Ikena Oncology (IKNA) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Ikena Oncology in October 2026.
Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.
Ikena Oncology (IKNA) Stock Forecast
Analyst price target, next 12 months
$4.00
+267.0% vs today's $1.09
Price range over the last 12 months
Close to its 12-month low
Analysts covering Ikena Oncology have a consensus 12-month target of $4.00, above the current price of $1.09.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 10 Apr 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IKENA's stock with a target price of $4, indicating good growth potential.
Financial Health
IKENA Oncology is showing strong cash flow and book value per share, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.